Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
1.
Clin Transl Oncol ; 23(2): 311-317, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32562197

RESUMEN

PURPOSE: Baseline LDH, derived neutrophil-lymphocyte ratio (dNLR) and immune-related adverse events (irAEs) are associated with outcomes of patients with metastatic melanoma (MM). We hypothesized whether dynamic shifts in LDH, dNLR and incidence of irAEs may impact the prognosis of MM patients treated with anti-CTLA4 or anti-PD1 as single agents. METHODS: Retrospective analysis of medical charts from MM patients with prospective monitoring of dNLR, LDH values and irAE incidence. Primary endpoint was overall survival (OS). RESULTS: Patients switching from either high dNLR (≥2.5) to low dNLR (HR: 0.14; 0.03-0.74; p = 0.02) or high LDH (≥1.5 × ULN) to low LDH levels (HR: 0.08; 0.01-0.68; p = 0.02) had significantly better OS than those with high dNLR or LDH scores at the end of cycle 2. Longer OS was also observed in patients developing irAEs ≥ grade 2 as compared to no irAEs (HR: 0.2; 0.05-0.89; p = 0.03). CONCLUSIONS: We found that major shifts in dNLR and LDH measures from baseline to cycle 2 measures and shifts from baseline to cycle 2 are significantly associated with OS in MM patients receiving single agent anti-PD1 therapy. Laboratory changes and clinical variables may help optimize prognostic estimates.


Asunto(s)
Biomarcadores de Tumor/sangre , Inmunoterapia , Lactato Deshidrogenasas/sangre , Linfocitos/citología , Melanoma/mortalidad , Neutrófilos/citología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales Humanizados/uso terapéutico , Femenino , Humanos , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Inmunoterapia/efectos adversos , Ipilimumab/uso terapéutico , Masculino , Melanoma/sangre , Melanoma/secundario , Melanoma/terapia , Persona de Mediana Edad , Nivolumab/uso terapéutico , Estudios Prospectivos , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
2.
Actas Dermosifiliogr (Engl Ed) ; 111(10): 815-821, 2020 Dec.
Artículo en Inglés, Español | MEDLINE | ID: mdl-32910922

RESUMEN

Teledermatology has facilitated specialist care during the crisis caused by the coronavirus disease 2019 pandemic, eliminating unnecessary office visits and the possible exposure of patients or dermatologists. However, teledermatology brings forward certain ethical and medicolegal questions. A medical consultation in which the patient is not physically present is still a medical act, to which all the usual ethical and medicolegal considerations and consequences apply. The patient's right to autonomy and privacy, confidentiality, and data protection must be guaranteed. The patient must agree to remote consultation by giving informed consent, for which a safeguard clause should be included. Well-defined practice guidelines and uniform legislation are required to preserve the highest level of safety for transferred data. Adequate training is also needed to prevent circumstances involving what might be termed «telemalpractice¼.


Asunto(s)
COVID-19/epidemiología , Pandemias , SARS-CoV-2 , Telemedicina , Lista de Verificación , Confidencialidad , Atención a la Salud/legislación & jurisprudencia , Dermatología/ética , Dermatología/legislación & jurisprudencia , Dermatología/métodos , Medicina Basada en la Evidencia , Humanos , Consentimiento Informado , Mala Praxis , Aceptación de la Atención de Salud , Autonomía Personal , España/epidemiología , Telemedicina/ética , Telemedicina/legislación & jurisprudencia , Telemedicina/métodos
4.
Actas Dermosifiliogr (Engl Ed) ; 110(8): 659-665, 2019 Oct.
Artículo en Inglés, Español | MEDLINE | ID: mdl-31153547

RESUMEN

BACKGROUND AND OBJECTIVE: Skin lesions are a common reason for consulting a primary care physician. Current legislation in Spain states that purely aesthetic skin problems that do not pose a health problem are not to be treated within the National Health Service. The aim of this study was to estimate the proportion of referrals from primary care physicians to dermatologists that were for cystic lesions or benign tumors and could potentially have been avoided. MATERIAL AND METHODS: We consulted cases registered in the DIADERM study dataset, which is representative of dermatology practice in Spain, and collected the main diagnoses given on referring patients from primary care. A referral diagnosis was classified as potentially avoidable if it corresponded to one of the primary care discharge diagnoses listed in a consensus paper of the Andalusian section of the Spanish Academy of Dermatology and Venereology (AEDV). RESULTS: We collected 2171 main reasons for first-visit referrals to dermatologists; 686 of them (31.6%) were for cystic lesions or benign tumors and classified as potentially avoidable. In 478 cases (22%) the patients were discharged on the first visit. The most frequent diagnoses in such cases were seborrheic keratosis (9.3%) and melanocytic nevus (8.6%). CONCLUSIONS: Nearly a third of referrals from primary care to a dermatologist were for cystic lesions and benign tumors and could have been avoided. A clearer understanding of our caseload can be useful for improving planning, training, and health care system management.


Asunto(s)
Dermatología/estadística & datos numéricos , Mal Uso de los Servicios de Salud/estadística & datos numéricos , Atención Primaria de Salud/estadística & datos numéricos , Derivación y Consulta/estadística & datos numéricos , Enfermedades de la Piel/diagnóstico , Quistes/diagnóstico , Mal Uso de los Servicios de Salud/prevención & control , Humanos , Queratosis Seborreica/diagnóstico , España
5.
Clin Exp Dermatol ; 44(4): e103-e109, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30701578

RESUMEN

BACKGROUND: Solid-organ transplant recipients (SOTRs) are at risk of developing vitamin D deficiency, mainly caused by reduced sunlight exposure with subsequent low vitamin D synthesis in the skin. AIM: To analyse whether SOTRs from a Spanish Mediterranean region were vitamin D-deficient. METHODS: This was a cross-sectional, descriptive and observational study in a transplantation-specialized Dermatological Unit from a Mediterranean area to determine the calcidiol levels of a cohort of 78 consecutively attending patients not receiving vitamin D supplements. Serum 25(OH)D3 levels were determined and clinical characteristics were collected. Logistic regression analysis was used to analyse variables associated with dichotomized 25(OH)D3 levels (≤ or > 10 ng/mL). RESULTS: The cohort comprised 30 lung, 29 kidney and 19 liver transplant recipients. Mean calcidiol was 18 ± 9 ng/mL. Deficiency of 25(OH)D3 was present in 19% of patients, while 68% had insufficient levels and 13% had sufficient levels. Following multivariate logistic regression analysis, the season of blood sampling remained the only predictor of deficient 25(OH)D3 levels. CONCLUSION: Despite living in a mid-latitude country with sunny weather, our SOTR population was at high risk of developing hypovitaminosis D, especially in autumn/winter. Avoiding sun exposure is important to prevent skin cancer, but careful monitoring of vitamin D status is recommended, with supplementation if hypovitaminosis D is detected.


Asunto(s)
Luz Solar/efectos adversos , Receptores de Trasplantes/estadística & datos numéricos , Trasplantes/estadística & datos numéricos , Deficiencia de Vitamina D/etiología , Adulto , Anciano , Calcifediol/sangre , Estudios Transversales , Femenino , Humanos , Masculino , Región Mediterránea/epidemiología , Persona de Mediana Edad , Factores de Riesgo , Estaciones del Año , España/epidemiología , Trasplantes/metabolismo , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/epidemiología
6.
Oncogene ; 36(41): 5695-5708, 2017 10 12.
Artículo en Inglés | MEDLINE | ID: mdl-28581514

RESUMEN

Despite the promising targeted and immune-based interventions in melanoma treatment, long-lasting responses are limited. Melanoma cells present an aberrant redox state that leads to the production of toxic aldehydes that must be converted into less reactive molecules. Targeting the detoxification machinery constitutes a novel therapeutic avenue for melanoma. Here, using 56 cell lines representing nine different tumor types, we demonstrate that melanoma cells exhibit a strong correlation between reactive oxygen species amounts and aldehyde dehydrogenase 1 (ALDH1) activity. We found that ALDH1A3 is upregulated by epigenetic mechanisms in melanoma cells compared with normal melanocytes. Furthermore, it is highly expressed in a large percentage of human nevi and melanomas during melanocyte transformation, which is consistent with the data from the TCGA, CCLE and protein atlas databases. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. Interestingly, DIMATE also targeted the slow cycling label-retaining tumor cell population containing the tumorigenic and chemoresistant cells. Our findings suggest that aldehyde detoxification is relevant metabolic mechanism in melanoma cells, which can be used as a novel approach for melanoma treatment.


Asunto(s)
Aldehído Oxidorreductasas/genética , Alquinos/administración & dosificación , Melanocitos/efectos de los fármacos , Melanoma/tratamiento farmacológico , Compuestos de Sulfhidrilo/administración & dosificación , Aldehído Oxidorreductasas/antagonistas & inhibidores , Animales , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Neoplásica/genética , Epigénesis Genética , Regulación Neoplásica de la Expresión Génica , Humanos , Melanocitos/patología , Melanoma/genética , Melanoma/patología , Ratones , Células Madre Neoplásicas/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto
9.
Actas Dermosifiliogr ; 107(2): 125-32, 2016 Mar.
Artículo en Inglés, Español | MEDLINE | ID: mdl-26691244

RESUMEN

BACKGROUND: Skin problems are among the most frequent reasons for seeking medical attention in primary care. In recent years, as a result of the process of adapting medical curricula to the requirements of the European Higher Education Area, the amount of time students spend learning the concepts of dermatology has been reduced in many universities. MATERIAL AND METHODS: In order to reach a consensus on core content for undergraduate education in dermatology, we sent a survey to the 57 members of the instructors' group of the Spanish Academy of Dermatology and Venereology (AEDV), asking their opinions on what objectives should be set for a dermatology course in Spain. A total of 131 previously selected objectives were listed. We then applied the Delphi method to achieve consensus on which ones the respondents considered important or very important (score≥4 on a Likert scale). RESULTS: Nineteen responses (33%) were received. On the second round of the Delphi process, 68 objectives achieved average scores of at least 4. The respondents emphasized that graduates should understand the structure and functions of the skin and know about bacterial, viral, and fungal skin infections, the most common sexually transmitted diseases (STDs), and the 4 main inflammatory dermatoses. Students should also learn about common complaints, such as itching and bald patches; the management of dermatologic emergencies; purpura and erythema nodosum as signs of internal disease; and the prevention of STDs and skin cancer. During clinical clerkships students should acquire the communication skills they will need to interview patients, write up a patient's medical history, and refer the patient to a specialist. CONCLUSIONS: The AEDV's group of instructors have defined their recommendations on the core content that medical faculties should adopt for the undergraduate subject of dermatology in Spain.


Asunto(s)
Curriculum , Dermatología/educación , Educación de Pregrado en Medicina , Venereología/educación , Humanos , España
10.
J Eur Acad Dermatol Venereol ; 29(1): 56-60, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24629001

RESUMEN

INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic skin disease which causes a great impact in the quality of life. Multiple therapeutic options have been proposed, and recently the potential use of biological drugs in severe cases has been postulated. MATERIAL AND METHODS: A retrospective study from seven tertiary Spanish centers reviewing the charts of patients with HS treated with biological drugs was performed. Retrieved information included epidemiological data, clinical features, pain intensity, Hurley stage, laboratory data and therapeutic outcomes. RESULTS: Nineteen patients were included in the study; 10 men (52.6%) and 9 women. Eight patients (42%) showed a Hurley severity stage II and 11 a stage III (57.8%). Adalimumab was prescribed as the first biological treatment in nine out of 19 cases (47.3%), whereas infliximab was prescribed in seven cases (36.8%), ustekinumab in two cases (10.5%) and etanercept in one (5.2%). A complete response was observed in three patients (two cases with infliximab and one case with ustekinumab), a partial improvement in 10 patients and in six patients no clinical improvement was noted. One patient referred worsening of the skin symptoms. In 6 cases, a second biological treatment was prescribed. In three of such cases, a partial improvement was noted, whereas in three cases no clinical improvement was observed. In two cases a switch to a third biological drug was indicated, with a partial improvement in one case. DISCUSSION AND CONCLUSIONS: Biological drugs could be a potential and effective therapeutic option for patients with severe HS. Complete and persistent clinical responses are rarely obtained (15%) and partial responses are achieved in approximately 50% of patients. No specific markers for a therapeutic response have been identified. No definitive conclusions regarding the most effective biological drug for HS could be drawn. Higher dosage schedules seem to be associated with higher response rates. The lack of response of one particular drug does not preclude a potential efficacy to another biological treatment.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Terapia Biológica , Hidradenitis Supurativa/tratamiento farmacológico , Inmunoglobulina G/uso terapéutico , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Adalimumab , Adolescente , Adulto , Sustitución de Medicamentos , Etanercept , Femenino , Humanos , Infliximab , Masculino , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Ustekinumab , Adulto Joven
13.
Arch Dermatol Res ; 306(1): 93-5, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24173126

RESUMEN

The association between beta human papillomavirus (HPV) types and cutaneous squamous cell carcinomas (cSCCs) is controversial. Several studies have found such an association, especially at early stages of carcinogenesis, but the presence of beta HPV types in aggressive cSCCs has only been reported in three patients previously. We aimed to search for beta HPV DNA in primary cSCCs and their corresponding lymph node metastases in a series of patients. The presence of DNA from 25 beta HPV types was determined using a multiplex PCR protocol in 35 primary cSCCs from 35 patients and their corresponding lymph node metastases. DNA from beta HPV types was detected in 9 % of primary cSCCs and in 13 % of metastases. No primary cutaneous SCC or lymphatic metastases were found to share the same HPV DNA. These data suggest that beta HPV types do not play an etiopathogenic role in advanced stages of squamous cell carcinogenesis.


Asunto(s)
Betapapillomavirus/genética , Carcinoma de Células Escamosas/genética , Metástasis Linfática/genética , Infecciones por Papillomavirus/genética , Neoplasias Cutáneas/genética , Anciano , Anciano de 80 o más Años , Betapapillomavirus/clasificación , Betapapillomavirus/aislamiento & purificación , Carcinoma de Células Escamosas/virología , ADN Viral , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Papillomavirus/virología , Neoplasias Cutáneas/virología
14.
Actas Dermosifiliogr ; 104(8): 694-709, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24018211

RESUMEN

Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic.


Asunto(s)
Factores Biológicos/uso terapéutico , Medicina Basada en la Evidencia , Psoriasis/tratamiento farmacológico , Acitretina/uso terapéutico , Adulto , Factores de Edad , Artritis Psoriásica/tratamiento farmacológico , Factores Biológicos/efectos adversos , Factores Biológicos/economía , Niño , Ensayos Clínicos como Asunto , Terapia Combinada , Análisis Costo-Beneficio , Sustitución de Medicamentos , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Metaanálisis como Asunto , Estudios Multicéntricos como Asunto , Fotoquimioterapia , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Factores Sexuales , España , Insuficiencia del Tratamiento , Resultado del Tratamiento
15.
Actas Dermosifiliogr ; 104(10): 890-6, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23809583

RESUMEN

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a rare disease that represents a heavy burden for both the patient and the health care system. There are currently no data on the prevalence of DEB in Spain. OBJECTIVE: To determine the prevalence of DEB in Spain. METHODS: We used data from 3 incomplete population-based sources (hospital dermatology departments, diagnostic laboratories performing antigenic mapping, genetic testing or both, and the Spanish Association of Epidermolysis Bullosa Patients [DEBRA]) and combined them using the 3-source capture-recapture methodology. RESULTS: We identified 152 living DEB patients. The estimated prevalence of DEB was 6.0 cases per million (95% CI, 4.2-11.8) in adults and 15.3 (95% CI, 10.4-40.8) in children under 18 years of age. The data indicated that 77% of the patients were not being followed up in specialized centers of reference; 65% had not had a genetic diagnosis, and 76% were not members of DEBRA. CONCLUSIONS: The prevalence of DEB in Spain is 6.0 patients per million (95% CI, 4.2-11.8), a figure higher than previous estimates in many areas, but similar to those found in other southern Europe countries. The north-south difference may represent real geographic differences in prevalence, but it might be due to the fact that most of the data come from registries with a lower than expected catchment. Many patients are not being followed up in centers of reference, do not have genetic diagnosis, and are not members of patients' associations, suggesting that there is room for considerable improvement in their care.


Asunto(s)
Epidermólisis Ampollosa Distrófica/epidemiología , Epidermólisis Ampollosa Distrófica/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Estudios Transversales , Necesidades y Demandas de Servicios de Salud/estadística & datos numéricos , Humanos , Lactante , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Mejoramiento de la Calidad , España/epidemiología , Adulto Joven
16.
Actas Dermosifiliogr ; 104(2): 133-40, 2013 Mar.
Artículo en Inglés, Español | MEDLINE | ID: mdl-22835227

RESUMEN

BACKGROUND: Complete surgical excision is the most common treatment for basal cell carcinoma (BCC), and this intervention is often performed by surgeons who are not dermatologists (e.g., plastic surgeons, general surgeons, oral and maxillofacial surgeons, ophthalmologists, and otorhinolaryngologists). OBJECTIVES: To determine positive margin rates in BCCs removed by surgeons from different specialties and to identify clinical and pathologic factors that might explain potential differences between specialties. METHODS: We retrospectively reviewed the pathology reports of all BCCs diagnosed at Hospital Universitari Vall d'Hebron between January 2009 and March 2001. The statistical methods included a descriptive analysis of clinical and pathologic variables, standard statistical analyses, and multivariate logistic regression. RESULTS: We included 921 BCCs from 750 patients; 549 of the tumors had been excised by a dermatologist. The overall positive margin rate was 12.6%, but the rate for tumors removed by dermatologists was significantly lower than that for those removed by other specialists (6.7% vs 21.5%). There was a 3.8-fold increased relative risk of positive margins following excision by a surgeon who was not a dermatologist, independently of patient age, tumor site, maximum diameter of the resected specimen, and histologic subtype. CONCLUSIONS: Accurate macroscopic identification of tumor margins, which are often difficult to see, and familiarity with the natural history of BCC are key factors in the successful surgical treatment of BCCs. The higher rate of tumor-free margins achieved by dermatologists in this study is probably mainly due to their greater experience in these 2 areas.


Asunto(s)
Carcinoma Basocelular/patología , Carcinoma Basocelular/cirugía , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/cirugía , Anciano , Femenino , Humanos , Masculino , Estudios Retrospectivos , Especialidades Quirúrgicas
17.
Actas Dermosifiliogr ; 103(6): 478-87, 2012.
Artículo en Español | MEDLINE | ID: mdl-22261674

RESUMEN

Penile squamous cell carcinoma (SCC) is uncommon in Europe, where it accounts for approximately 0.7% of all malignant tumors in men. The main risk factors are poor hygiene, lack of circumcision, human papillomavirus (HPV) infection, and certain chronic inflammatory skin diseases. HPV infection is detected in 70% to 100% of all penile in situ SCCs and in 30% to 50% of invasive forms of the disease, mainly basaloid and warty SCCs. In situ tumors can be treated conservatively, but close monitoring is essential as they become invasive in between 1% and 30% of cases. The treatment of choice for penile SCC is surgery. Inguinal lymph node irradiation is no longer recommended as a prophylactic measure, and it appears that selective lymph node biopsy might be useful for reducing the morbidity associated with prophylactic inguinal lymph node dissection. Survival is directly related to lymph node involvement. Improving our knowledge of underlying molecular changes and their associated genotypes will open up new therapeutic pathways.


Asunto(s)
Carcinoma de Células Escamosas/epidemiología , Neoplasias del Pene/epidemiología , Anciano , Balanitis/complicaciones , Balanitis/patología , Carcinoma in Situ/epidemiología , Carcinoma in Situ/cirugía , Carcinoma in Situ/virología , Carcinoma de Células Escamosas/cirugía , Carcinoma de Células Escamosas/virología , Circuncisión Masculina , Condiloma Acuminado/epidemiología , Condiloma Acuminado/virología , Europa (Continente)/epidemiología , Papillomavirus Humano 16/patogenicidad , Humanos , Higiene , Escisión del Ganglio Linfático , Metástasis Linfática , Masculino , Invasividad Neoplásica , Estadificación de Neoplasias , Infecciones por Papillomavirus/epidemiología , Neoplasias del Pene/clasificación , Neoplasias del Pene/prevención & control , Neoplasias del Pene/cirugía , Neoplasias del Pene/virología , Fimosis/complicaciones , Fimosis/patología , Lesiones Precancerosas/epidemiología , Lesiones Precancerosas/patología , Pronóstico , Factores de Riesgo
18.
Br J Dermatol ; 166(4): 830-8, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22121851

RESUMEN

BACKGROUND: Conradi-Hünermann-Happle syndrome (CDPX2, OMIM 302960) is an inherited X-linked dominant variant of chondrodysplasia punctata which primarily affects the skin, bones and eyes. CDPX2 results from mutations in EBP (emopamil binding protein), and presents with increased levels of sterol precursors 8(9)-cholesterol and 8-dehydrocholesterol. OBJECTIVES: To expand the understanding of CDPX2, clinically, biochemically and genetically. METHODS: We present one of the largest series reported to date, including 13 female patients belonging to nine Spanish families. Patients were studied biochemically using gas chromatography-mass spectrometry, genetically using polymerase chain reaction and in their methylation status using the HUMARA assay. RESULTS: In our cases, there was a clear relationship between abnormal sterol profile and the EBP gene mutation. We describe three novel mutations in the EBP gene. EBP mutations were inherited in three out of nine families and were sporadic in the remaining cases. CONCLUSIONS: No clear genotype-phenotype correlation was found. Patients' biochemical profiles did not reveal a relationship between sterol profiles and severity of disease. A skewed X-chromosome inactivation may explain the clinical phenotype in CDPX2 in some familial cases.


Asunto(s)
Condrodisplasia Punctata/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Mutación/genética , Esteroide Isomerasas/genética , Inactivación del Cromosoma X/genética , Adulto , Colestadienoles/metabolismo , Colesterol/metabolismo , Condrodisplasia Punctata/metabolismo , Análisis Mutacional de ADN/métodos , Femenino , Enfermedades Genéticas Ligadas al Cromosoma X/metabolismo , Genotipo , Humanos , Lactante , Fenotipo , España
19.
J Eur Acad Dermatol Venereol ; 25(10): 1153-9, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21198948

RESUMEN

BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening drug reactions considered to be part of the spectrum of a single pathological process. OBJECTIVE: To describe the clinical and epidemiological characteristics of SJS/TEN in children attended at our hospital. MATERIALS AND METHODS: Retrospective study of children diagnosed with SJS/TEN between 1999 and 2009 in a University Hospital provided with regional-level burn and paediatric intensive care units. RESULTS: We found 14 paediatric patients (eight SJS and six TEN). They presented an average of 60% of the body surface area affected and 31% of epidermal sloughing. The average of suspected drugs was 1.7 per patient, anticonvulsants (carbamazepine, phenytoin and lamotrigine) and antibiotics (penicillin and macrolides) being the most frequent ones. Silver sulfadiazine was the topical treatment most frequently used, 86% of patients received systemic steroids and 28.5% intravenous immunoglobulins. One patient died. CONCLUSIONS: The SJS/TEN complex is a true dermatological critical condition that also affects children. Any drug can be the causative agent, more frequently anticonvulsants and antibiotics. Depending on the extension of the affected body surface, patients should be rapidly admitted to a critical care area with experience in the care of burn patients. Discontinuation of the suspected offending drugs is mandatory. Optimal supportive care and management of denuded skin areas are still the mainstay of treatment. The use of specific therapies remains controversial. Compared with adults, the disease in children seems to be milder with lower mortality.


Asunto(s)
Síndrome de Stevens-Johnson , Adolescente , Corticoesteroides/uso terapéutico , Antibacterianos/efectos adversos , Anticonvulsivantes/efectos adversos , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Incidencia , Lactante , Masculino , Estudios Retrospectivos , Síndrome de Stevens-Johnson/tratamiento farmacológico , Síndrome de Stevens-Johnson/epidemiología , Síndrome de Stevens-Johnson/etiología , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA